By Ben Butkus
Enigma Diagnostics said this week that it has commenced clinical trials in the US for its first diagnostic assay, a real-time PCR-based point-of-care test for influenza A and B.
Enigma will go it alone, however, as the company confirmed that it is no longer commercializing its test, the Enigma ML Influenza A/B detection assay, in partnership with GlaxoSmithKline as was previously reported.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
